|Home | About | Journals | Submit | Contact Us | Français|
Second-hand smoke (SHS) exposure is estimated to kill 600 000 people worldwide annually. The WHO recommends that smoke-free indoor public environments are enforced through national legislation. Such regulations have been shown to reduce SHS exposure and, consequently, respiratory and cardiovascular morbidity. Evidence of particular health benefit in children is now emerging, including reductions in low birthweight deliveries, preterm birth and asthma exacerbations. We aim to comprehensively assess the impact of smoke-free legislation on fetal, infant and childhood outcomes. This can inform further development and implementation of global policy and strategies to reduce early life SHS exposure.
Two authors will search online databases (1975–present; no language restrictions) of published and unpublished/in-progress studies, and references and citations to articles of interest. We will consult experts in the field to identify additional studies. Studies should describe associations between comprehensive or partial smoking bans in public places and health outcomes among children (0–12 years): stillbirth, preterm birth, low birth weight, small for gestational age, perinatal mortality, congenital anomalies, bronchopulmonary dysplasia, upper and lower respiratory infections and wheezing disorders including asthma. The Cochrane Effectiveness Practice and Organisational Care (EPOC)-defined study designs are eligible. Study quality will be assessed using the Cochrane 7-domain-based evaluation for randomised and clinical trials, and EPOC criteria for quasiexperimental studies. Data will be extracted by two reviewers and presented in tabular and narrative form. Meta-analysis will be undertaken using random-effects models, and generic inverse variance analysis for adjusted effect estimates. We will report sensitivity analyses according to study quality and design characteristics, and subgroup analyses according to coverage of ban, age group and parental/maternal smoking status. Publication bias will be assessed.
Ethics assessment is not required.
Will be presented in one manuscript. The protocol is registered with PROSPERO, registration number CRD42013003522.
Tobacco use kills more than five million people annually, making it the leading global cause of preventable death.1 It is estimated that second-hand smoke (SHS) exposure kills an additional 600 000 people worldwide each year, including 165 000 children under 15 years.1 2 Among non-smoking adults, SHS exposure furthermore increases the incidence of asthma, lung cancer and ischaemic heart disease.2 In an attempt to reduce this substantial burden on second-hand or passive smokers, the WHO has recommended that smoke-free indoor public environments are enforced through national legislation and that educational strategies are pursued in parallel to reduce SHS exposure in the home.3 Studies have since shown that smoking bans effectively reduce SHS exposure, even in the absence of an overall decline in smoking prevalence in the population.4 More importantly, consistent health effects have been reported in a recent Cochrane review summarising 25 studies including reductions in respiratory symptoms, sensory symptoms and admissions for acute myocardial infarction (AMI).4 These effects have since been reproduced by others,5–7 while additional studies also demonstrated reductions in sudden cardiac arrest and mortality from AMI in response to implementation of smoke-free legislation.8 9
As developing individuals, children are particularly vulnerable to the negative effects of SHS, which may even ensue before birth.10–12 Furthermore, they are unable to influence their own degree of exposure. Antenatal SHS exposure puts unborn babies at risk for stillbirth,13 preterm delivery,14 growth retardation,12 15 congenital anomalies,15 16 bronchopulmonary dysplasia17 and respiratory infections and asthma in childhood.11 18 Worldwide, at least 40% of children are regularly exposed to SHS after birth, additionally predisposing them to upper and lower respiratory infections as well as asthma.2 Children thus bear an important part of the disease burden associated with SHS and are likely to particularly benefit from restrictive legislation. Indeed, several recent studies provide evidence for beneficial effects of smoke-free laws on infant and child health. Epidemiological evaluations of the 2006 Scottish smoking ban have demonstrated reductions in low birth weight, preterm birth and childhood asthma hospitalisations following its introduction.19 20 These results have now been confirmed in several follow-up studies.21 22
Despite this increasing evidence for particular health benefits of smoke-free legislation in children, the currently available systematic reviews assessing its health effects in general have not included any studies on perinatal or paediatric outcomes.4 23 24 A comprehensive estimate of the benefits associated with smoke-free legislation in newborns and children will inform the development and implementation of global policy and strategies to further reduce SHS exposure in this particularly vulnerable population. Therefore, we will undertake a systematic review and meta-analysis of studies on fetal, infant and child-health outcomes related to the introduction of smoke-free legislation in order to obtain the most comprehensive assessment to date of its effectiveness in improving the health of babies and children worldwide.
Systematic review and meta-analysis.
Types of interventions
Types of studies
Types of participants
Types of outcome measures
Outcome measures should preferably be reported or documented by a health worker; alternatively, parent-reported outcomes, parent-reported physician diagnoses or diagnoses based on medication use or prescriptions (eg, inhaled corticosteroids as a surrogate for asthma diagnosis) are acceptable. Outcomes may be defined as absolute (eg, incidence) or relative disease occurrence (eg, relative risk and OR), or by associated health facility use (eg, doctor or emergency department visits and hospitalisation). Outcomes of interest are selected based on their relevance to fetal, infant and/or paediatric health and their recognised association between antenatal and/or postnatal SHS exposure. In addition, selection of primary outcomes is based on the magnitude of their burden for paediatric health, as well as their recognised reduction after the introduction of smoke-free legislation as shown by at least one high-quality study.
When outcome definitions used in selected reports differ from the criteria outlined above, two authors (JVB and UN) will make a decision regarding their inclusion in any meta-analyses. This will be based on the degree of deviation from the defined outcome criteria, and the expected effect that this may have on the analyses. A third author will be consulted to resolve any disagreement. Additional sensitivity analyses will be considered to explore the effect of inclusion of different outcome definitions.
Two authors (JVB and UN) will search databases and screen titles and abstracts for potentially eligible studies. Disagreement will be resolved by consensus, or arbitration involving a third author where necessary. Full text articles will be retrieved for selected studies, and two authors (JVB and UN) will assess whether these meet inclusion criteria. Disagreement will be resolved by discussion among reviewers, with referral to a third author if necessary. Reasons for exclusion of studies will be noted.
Study quality will be assessed using the Cochrane handbook 7-domain-based evaluation for RCTs, quasi-RCTs and CCTs (Cochrane handbook, table 8.5.a).27 For controlled before-and-after studies and ITS analyses, EPOC guidelines will be used.28 We will grade each parameter of trial quality: A, low risk of bias; B, moderate risk of bias; C, high risk of bias and an overall assessment for each controlled trial using the same three criteria will be made. Risk of bias will be assessed in part by recording design features (assessed by a formal list in the Cochrane handbook, table 13.2.a) as well as by whether or not confounding is accounted for.27 The primary confounder considered is maternal or parental smoking. Documentation of maternal/parental smoking according to smoke-free legislation status will be assessed, as well as adjustment of the final analyses for a potential confounding effect of this variable. All assessments of study quality will be performed by two authors (JVB and UN), with any disagreement resolved by consensus, or arbitration involving a third author where necessary.
Data will be extracted from selected papers by two reviewers (JVB and UN), with any disagreement resolved by consensus, or arbitration involving a third author where necessary. Corresponding authors of eligible studies will be contacted to clarify any ambiguities. The following information will be extracted:
Data will be presented in tabular and narrative forms. If possible, meta-analysis will be performed on similar studies reporting main, primary and secondary outcomes, and be presented in forest plots. Choice of the statistical tests used will depend on the nature of the outcome variable. We will apply a random effects model in all analyses, given the expected degree of heterogeneity in the population and design between studies. Heterogeneity will be assessed both qualitatively and quantitatively using the I² statistic. Meta-analysis will not be undertaken when I² is equal to or greater than 75%. Where possible, adjusted effect estimates will be pooled in meta-analyses using generic inverse-variance analysis. Adjusted effect estimates derived from the most adjusted model in the original paper will be selected for these analyses. Point estimates and 95% CIs will be reported for all analyses.
Sensitivity analyses will be performed in subgroups of study quality and of design characteristics (randomised vs non-randomised; prospective vs retrospective). If possible, analyses will be performed in subgroups made according to the following defining parameters: setting of smoking restriction (comprehensive vs location-specific (eg, working space, bars and restaurants)), age of study individuals (under 5 vs 5 years and older), smoking status in the home or maternal smoking for perinatal outcomes. For meta-analyses of adjusted effect estimates, an additional sensitivity analysis will be performed according to whether or not maternal or parental smoking was part of the adjusted model in the original study.
For any meta-analysis that includes 10 or more studies, publication bias will be assessed visually through Funnel plots and tested by Egger's regression test and Begg's rank correlation test.29 30 All statistical analyses will be performed using Stata.
As no primary data collection will be undertaken, no additional formal ethical assessment and informed consent are required.
The systematic review protocol is registered with the PROSPERO International Prospective Register of Systematic Reviews (http://www.crd.york.ac.uk/prospero). Findings will be summarised in a single manuscript.
Start date: 1 January 2013
Finishing date: 31 March 2014
Reporting date: 31 March 2014
We thank Marshall Dozier for valuable feedback on our search strategy, and the Netherlands Asthma Foundation, the Maastricht University Medical Centre, the Thrasher Research Fund and the International Pediatric Research Foundation for funding this work.
Contributors: JVB conceived the study and prepared the initial protocol draft. JVB, UN, CPvS and AS were involved in study design, protocol and manuscript development. JVB and UN designed the search strategy. All authors read and approved the final version of the manuscript.
Funding: This work was supported by the Thrasher Research Fund Early Career Award NR-0166; The Netherlands Asthma Foundation Long Term Fellowship 184.108.40.206FE (JVB); Maastricht University Medical Centre Kootstra Talent Fellowship (JVB) and the International Pediatric Research Foundation Young Investigator Exchange Programme (JVB).
Competing interests: None.
Provenance and peer review: Not commissioned; externally peer reviewed.